STOCK TITAN

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

IDEAYA Biosciences (NASDAQ: IDYA) announced the granting of inducement stock options to a new employee. The Compensation Committee approved non-qualified stock options to purchase 31,400 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.

The stock options were granted at an exercise price of $24.35 per share, matching IDEAYA's closing price on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction – IDYA

-0.33%
1 alert
-0.33% News Effect

On the day this news was published, IDYA declined 0.33%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., Aug. 1, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on July 31, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 31,400 shares of the Company's common stock to a newly hired employee. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individual entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $24.35 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer 
investor@ideayabio.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302519217.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What stock options did IDEAYA Biosciences (IDYA) grant to its new employee?

IDEAYA granted non-qualified stock options to purchase 31,400 shares of common stock at an exercise price of $24.35 per share.

What is the vesting schedule for IDEAYA's (IDYA) newly granted stock options?

The options vest over 4 years, with 25% vesting after the first year and the remaining 75% vesting in monthly installments over the following three years.

What is the purpose of IDEAYA's (IDYA) 2023 Inducement Plan?

The 2023 Inducement Plan is used exclusively for granting equity awards to new employees as an inducement for joining IDEAYA, in accordance with Nasdaq Listing Rule 5635(c)(4).

How long is the term of IDEAYA's (IDYA) newly granted stock options?

The stock options have a 10-year term from the date of grant.
Ideaya Biosciences

NASDAQ:IDYA

View IDYA Stock Overview

IDYA Rankings

IDYA Latest News

IDYA Latest SEC Filings

IDYA Stock Data

2.91B
87.00M
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO